vs
ADMA BIOLOGICS, INC.（ADMA）与Eventbrite, Inc.（EB）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Eventbrite, Inc.的1.9倍（$139.2M vs $73.5M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -11.1%，领先46.6%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -3.9%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-60.9M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -7.7%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
ADMA vs EB — 直观对比
营收规模更大
ADMA
是对方的1.9倍
$73.5M
营收增速更快
ADMA
高出22.3%
-3.9%
净利率更高
ADMA
高出46.6%
-11.1%
自由现金流更多
ADMA
多$95.4M
$-60.9M
两年增速更快
ADMA
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $73.5M |
| 净利润 | $49.4M | $-8.2M |
| 毛利率 | 63.8% | 68.1% |
| 营业利润率 | 45.1% | -12.4% |
| 净利率 | 35.5% | -11.1% |
| 营收同比 | 18.4% | -3.9% |
| 净利润同比 | -55.9% | 2.5% |
| 每股收益（稀释后） | $0.20 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAEB
| Q4 25 | $139.2M | $73.5M | ||
| Q3 25 | $134.2M | $71.7M | ||
| Q2 25 | $122.0M | $72.8M | ||
| Q1 25 | $114.8M | $73.8M | ||
| Q4 24 | $117.5M | $76.5M | ||
| Q3 24 | $119.8M | $77.8M | ||
| Q2 24 | $107.2M | $84.6M | ||
| Q1 24 | $81.9M | $86.3M |
净利润ADMAEB
| Q4 25 | $49.4M | $-8.2M | ||
| Q3 25 | $36.4M | $6.4M | ||
| Q2 25 | $34.2M | $-2.1M | ||
| Q1 25 | $26.9M | $-6.6M | ||
| Q4 24 | $111.9M | $-8.4M | ||
| Q3 24 | $35.9M | $-3.8M | ||
| Q2 24 | $32.1M | $1.1M | ||
| Q1 24 | $17.8M | $-4.5M |
毛利率ADMAEB
| Q4 25 | 63.8% | 68.1% | ||
| Q3 25 | 56.3% | 67.9% | ||
| Q2 25 | 55.1% | 67.5% | ||
| Q1 25 | 53.2% | 66.9% | ||
| Q4 24 | 53.9% | 68.2% | ||
| Q3 24 | 49.8% | 68.5% | ||
| Q2 24 | 53.6% | 70.9% | ||
| Q1 24 | 47.8% | 71.0% |
营业利润率ADMAEB
| Q4 25 | 45.1% | -12.4% | ||
| Q3 25 | 38.0% | -1.3% | ||
| Q2 25 | 35.1% | -8.7% | ||
| Q1 25 | 30.4% | -13.2% | ||
| Q4 24 | 32.6% | -10.2% | ||
| Q3 24 | 33.1% | -11.5% | ||
| Q2 24 | 36.6% | -7.6% | ||
| Q1 24 | 26.7% | -8.8% |
净利率ADMAEB
| Q4 25 | 35.5% | -11.1% | ||
| Q3 25 | 27.1% | 8.9% | ||
| Q2 25 | 28.1% | -2.9% | ||
| Q1 25 | 23.4% | -9.0% | ||
| Q4 24 | 95.2% | -11.0% | ||
| Q3 24 | 30.0% | -4.8% | ||
| Q2 24 | 29.9% | 1.3% | ||
| Q1 24 | 21.7% | -5.2% |
每股收益（稀释后）ADMAEB
| Q4 25 | $0.20 | $-0.08 | ||
| Q3 25 | $0.15 | $0.06 | ||
| Q2 25 | $0.14 | $-0.02 | ||
| Q1 25 | $0.11 | $-0.07 | ||
| Q4 24 | $0.45 | $-0.09 | ||
| Q3 24 | $0.15 | $-0.04 | ||
| Q2 24 | $0.13 | $0.01 | ||
| Q1 24 | $0.08 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $299.9M |
| 总债务越低越好 | $72.1M | $144.4M |
| 股东权益账面价值 | $477.3M | $179.1M |
| 总资产 | $624.2M | $647.2M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.81× |
8季度趋势，按日历期对齐
现金及短期投资ADMAEB
| Q4 25 | $87.6M | $299.9M | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | $441.5M | ||
| Q3 24 | $86.7M | $24.7M | ||
| Q2 24 | $88.2M | $56.7M | ||
| Q1 24 | $45.3M | $113.7M |
总债务ADMAEB
| Q4 25 | $72.1M | $144.4M | ||
| Q3 25 | $72.4M | $174.9M | ||
| Q2 25 | — | $241.3M | ||
| Q1 25 | — | $241.0M | ||
| Q4 24 | $72.3M | $240.7M | ||
| Q3 24 | — | $240.4M | ||
| Q2 24 | — | $358.7M | ||
| Q1 24 | — | $358.2M |
股东权益ADMAEB
| Q4 25 | $477.3M | $179.1M | ||
| Q3 25 | $431.2M | $189.1M | ||
| Q2 25 | $398.3M | $177.2M | ||
| Q1 25 | $373.4M | $173.3M | ||
| Q4 24 | $349.0M | $170.2M | ||
| Q3 24 | $231.9M | $179.8M | ||
| Q2 24 | $188.3M | $176.2M | ||
| Q1 24 | $153.7M | $184.1M |
总资产ADMAEB
| Q4 25 | $624.2M | $647.2M | ||
| Q3 25 | $568.7M | $744.6M | ||
| Q2 25 | $558.4M | $784.1M | ||
| Q1 25 | $510.6M | $812.3M | ||
| Q4 24 | $488.7M | $752.3M | ||
| Q3 24 | $390.6M | $817.4M | ||
| Q2 24 | $376.4M | $894.5M | ||
| Q1 24 | $350.9M | $952.2M |
负债/权益比ADMAEB
| Q4 25 | 0.15× | 0.81× | ||
| Q3 25 | 0.17× | 0.92× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | 0.21× | 1.41× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 2.04× | ||
| Q1 24 | — | 1.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $-60.8M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-60.9M |
| 自由现金流率自由现金流/营收 | 24.8% | -82.8% |
| 资本支出强度资本支出/营收 | 0.8% | 0.0% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $17.6M |
8季度趋势，按日历期对齐
经营现金流ADMAEB
| Q4 25 | $35.6M | $-60.8M | ||
| Q3 25 | $13.3M | $36.7M | ||
| Q2 25 | $21.1M | $-17.5M | ||
| Q1 25 | $-19.7M | $59.4M | ||
| Q4 24 | $50.2M | $-45.3M | ||
| Q3 24 | $25.0M | $44.6M | ||
| Q2 24 | $45.6M | $-32.3M | ||
| Q1 24 | $-2.2M | $68.6M |
自由现金流ADMAEB
| Q4 25 | $34.6M | $-60.9M | ||
| Q3 25 | $-1.1M | $36.6M | ||
| Q2 25 | $18.7M | $-17.5M | ||
| Q1 25 | $-24.4M | $59.4M | ||
| Q4 24 | $47.5M | $-45.3M | ||
| Q3 24 | $24.0M | $44.4M | ||
| Q2 24 | $43.6M | $-32.4M | ||
| Q1 24 | $-4.6M | $68.2M |
自由现金流率ADMAEB
| Q4 25 | 24.8% | -82.8% | ||
| Q3 25 | -0.8% | 51.1% | ||
| Q2 25 | 15.3% | -24.1% | ||
| Q1 25 | -21.2% | 80.4% | ||
| Q4 24 | 40.4% | -59.2% | ||
| Q3 24 | 20.0% | 57.1% | ||
| Q2 24 | 40.7% | -38.3% | ||
| Q1 24 | -5.6% | 79.1% |
资本支出强度ADMAEB
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 4.1% | 0.1% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.9% | 0.2% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 0.4% |
现金转化率ADMAEB
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 5.76× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -30.37× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
